The round was led by existing investors General Catalyst and international investment company Kinnevik, with participation from existing investors DFJ, Kleiner Perkins Caufield & Byers, Merck Global Health Innovation Fund, Microsoft Ventures, Sapphire Ventures, Zaffre Investments, and 7wire Ventures and new investor Echo Health Ventures. In conjunction with the funding, Chris Bischoff, Senior Investment Director for Kinnevik, is joining Livongo’s Board of Directors.
The company will use the funds to accelerate growth, continue to invest in data science, deepen integration with clients and partners, and develop its comprehensive consumer platform.
Led by Glen Tullman, Chief Executive Officer, Livongo currently offers Livongo for Diabetes and Livongo for Hypertension, which enable members to drive behavior change through the combination of consumer health technology, personalized recommendations, and real-time support at the point of impact.
Powered by advanced data science, the company creates personalized experiences, so they receive the right information, tools, and support, at the right time.
The company also announced a strategic partnership with Oregon-based Cambia Health Solutions – which reaches more than 70 million Americans nationwide – to improve the health of its members, beginning with diabetes.
Livongo and Cambia will also co-develop and market new offerings.
FinSMEs
12/04/2018